Home > Oncology > Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study

Amgen drug shrinks tumors in lung cancer patients with KRAS gene mutation -study


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
New England Journal of Medicine
Reuters - 21/09/2020 - An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in 32% of advanced lung cancer patients and 7% of those with colon cancer, according to data from an early-stage trial presented on Sunday. The median length of time that patients given the drug sotorasib lived before their disease worsened was 6.3 months for lung cancer patients and 4 months for colorectal cancer patients, the company said. Participants in the 129-patient study were followed for a median of 11.7 months. Patients in the Phase I trial involving several types of cancer were treated with once daily sotorasib. The oral medication is designed to target a mutated form of a gene known as KRAS that occurs in about 13% of non-small cell lung cancers (NSCLC), the most common type of lung cancer. The KRAS mutation is also found in 1% to 3% of colorectal and other cancers. Sotorasib is part of a growing trend of precision medicines that target gen...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on